Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy

Taku Fujimura; Yumi Kambayashi; Hisayuki Tono; Chinbing Lyu; Kentaro Ohuchi; Akira Hashimoto; Setsuya Aiba

doi:10.1111/dth.13672

Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy

Taku Fujimura, Yumi Kambayashi, Hisayuki Tono, Chinbing Lyu, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.

Original language	English
Article number	e13672
Journal	Dermatologic Therapy
Volume	33
Issue number	4
DOIs	https://doi.org/10.1111/dth.13672
Publication status	Published - 2020 Jul 1

Keywords

PD-1
PD-L1
cutaneous SCC
immunotherapy
nivolumab

ASJC Scopus subject areas

Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dth.13672

Cite this

@article{62ae33c8d51e4a46b62a9f40679e8efd,

title = "Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy",

abstract = "Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.",

keywords = "PD-1, PD-L1, cutaneous SCC, immunotherapy, nivolumab",

author = "Taku Fujimura and Yumi Kambayashi and Hisayuki Tono and Chinbing Lyu and Kentaro Ohuchi and Akira Hashimoto and Setsuya Aiba",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC.",

year = "2020",

month = jul,

day = "1",

doi = "10.1111/dth.13672",

language = "English",

volume = "33",

journal = "Dermatologic Therapy",

issn = "1396-0296",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy

AU - Fujimura, Taku

AU - Kambayashi, Yumi

AU - Tono, Hisayuki

AU - Lyu, Chinbing

AU - Ohuchi, Kentaro

AU - Hashimoto, Akira

AU - Aiba, Setsuya

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.

AB - Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.

KW - PD-1

KW - PD-L1

KW - cutaneous SCC

KW - immunotherapy

KW - nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85086456243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086456243&partnerID=8YFLogxK

U2 - 10.1111/dth.13672

DO - 10.1111/dth.13672

M3 - Article

C2 - 32449226

AN - SCOPUS:85086456243

VL - 33

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 4

M1 - e13672

ER -

Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this